Strides Arcolabs' injectable-drugs unit, @Agila_Specialties
Private Limited is up for sale and 'serious bidders' for the asset are Novartis and @Pfizer_Limited
along with U.S buyout fund KKR, ET stated.
Strides is expecting to receive anywhere between $1.6-2 Bn for the unit - more than twice its market value.
Strides provides Pfizer with generic versions of off-patent drugs through a partnership announced in 2010.